{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:15:56Z","timestamp":1787836556967,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Inflammatory Bowel Diseases (IBD) comprise ulcerative colitis (UC) and Crohn\u2019s disease (CD). Management of IBD requires assessment of disease activity, severity, extent and complications. Here, we describe the signal behavior of both CD and UC in\n                      <jats:sup>68<\/jats:sup>\n                      Gallium- fibroblast activation protein inhibitor-based radiopharmaceuticals-46-positron emission tomography (\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI-46-PET) and evaluate the potential of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI-46-PET for activity assessment in IBD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      This analysis includes data of 43 IBD patients and 43 control patients examined by\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI-46-PET\/computed tomography (CT). Disease activity of IBD patients was assessed by colonoscopy. FAPI-positive gastrointestinal tract (GIT)-findings and healthy appearing GI structures were contoured. Non-IBD related FAPI-positive GIT-findings were ruled out by interdisciplinary consensus. Static and dynamic PET-parameters of FAPI-positive IBD lesions and healthy appearing GI structures were extracted and PET signalling was analyzed with respect to IBD subtype and disease activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We examined 20 CD patients and 23 UC patients (29 with active, 14 with inactive disease). FAPI-uptake in most healthy appearing GI structures of IBD patients was significantly increased compared to controls. Of 80 FAPI-positive GIT-findings, 14 were ruled out as non-IBD related and 66 FAPI-positive IBD lesions were analyzed. We observed equally high lesional FAPI-uptake in CD and UC. All patients with active disease showed at least one intensively FAPI-positive IBD lesion, while only 4\/14 patients with inactive disease showed any FAPI-positive IBD lesion. Lesional and patientwise FAPI-uptake was significantly higher in active than in inactive disease. FAPI-positive IBD lesions showed a characteristic kinetic behaviour with two types of uptake patterns \u2013 one showing a continuous increase and the other an early peak followed by a plateau.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI-46-PET\/CT appears promising for assessing disease activity in terms of fibroblast activation in both CD and UC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07686-1","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:21:27Z","timestamp":1767421287000},"page":"3258-3270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["68Ga-FAPI PET\/CT for non-invasive characterization and activity assessment of ulcerative colitis and Crohn\u00b4s disease"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5346-6965","authenticated-orcid":false,"given":"Josefin","family":"Debus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"von G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ehehalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Spektor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mildenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Gauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik M.","family":"Glatting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schreckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-243X","authenticated-orcid":false,"given":"Manuel","family":"R\u00f6hrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"1","key":"7686_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","volume":"94","author":"GP Ramos","year":"2019","unstructured":"Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc. 2019;94(1):155\u201365.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"7686_CR2","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/nu11061398","volume":"11","author":"F Castro","year":"2019","unstructured":"Castro F, de Souza HSP. Dietary composition and effects in inflammatory bowel disease. Nutrients. 2019;11(6):1398.","journal-title":"Nutrients"},{"issue":"4","key":"7686_CR3","first-page":"678","volume":"29","author":"W Merkt","year":"2021","unstructured":"Merkt W, et al. Myofibroblast fate plasticity in tissue repair and fibrosis: deactivation, apoptosis,senescenceandreprogramming. WoundRepairandRegeneration. 2021;29(4):678\u201391.","journal-title":"WoundRepairandRegeneration"},{"key":"7686_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.semcdb.2019.12.008","volume":"101","author":"W Merkt","year":"2020","unstructured":"Merkt W, et al. Senotherapeutics: targeting senescence in idiopathic pulmonary fibrosis. Semin Cell Dev Biol. 2020;101:104\u201310.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"7686_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3\u201325.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"7686_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.crohns.2011.10.005","volume":"6","author":"U Navaneethan","year":"2012","unstructured":"Navaneethan U, et al. Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients. J Crohns Colitis. 2012;6(4):470\u20135.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"7686_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-4-9","volume":"4","author":"T De Lange","year":"2004","unstructured":"De Lange T, Larsen S, Aabakken L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol. 2004;4(1):9.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"7686_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jimaging9060115","volume":"9","author":"B Sun","year":"2023","unstructured":"Sun B, et al. Imaging of gastrointestinaltractailments. J Imaging. 2023;9(6):115.","journal-title":"J Imaging"},{"key":"7686_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/623036","volume":"2013","author":"AWJM Glaudemans","year":"2013","unstructured":"Glaudemans AWJM, et al. The use of 18F-FDG-PET\/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013;2013:1\u201314.","journal-title":"Clin Dev Immunol"},{"issue":"5","key":"7686_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.62347\/YXQT2560","volume":"14","author":"A Bhattaru","year":"2024","unstructured":"Bhattaru A, et al. 18F-FDG-PET and other imaging modalities in the diagnosis and management of inflammatory bowel disease. Am J Nucl Med Mol Imaging. 2024;14(5):295\u2013305.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"12","key":"7686_CR11","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.2967\/jnumed.123.265935","volume":"64","author":"F Rezazadeh","year":"2023","unstructured":"Rezazadeh F, Kilcline AP, Viola NT. Imaging agents for PET of inflammatory bowel disease: a review. J Nucl Med. 2023;64(12):1858\u201364.","journal-title":"J Nucl Med"},{"key":"7686_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082474","author":"J Langhorst","year":"2020","unstructured":"Langhorst J, et al. Diagnostic performance of simultaneous [18F]-FDG PET\/MR for assessing endoscopically active inflammation in patients with ulcerative colitis: a prospective study. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9082474.","journal-title":"J Clin Med"},{"issue":"9","key":"7686_CR13","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322.","journal-title":"J Nucl Med"},{"issue":"10","key":"7686_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60(10):1421\u20139.","journal-title":"J Nucl Med"},{"issue":"6","key":"7686_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, et al. 68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801\u20135.","journal-title":"J Nucl Med"},{"issue":"8","key":"7686_CR16","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","volume":"49","author":"M Li","year":"2022","unstructured":"Li M, et al. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022;49(8):2844\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7686_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.121.261925","volume":"63","author":"M R\u00f6hrich","year":"2022","unstructured":"R\u00f6hrich M, et al. Fibroblast activation protein-specific PET\/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study. J Nucl Med. 2022;63(1):127\u201333.","journal-title":"J Nucl Med"},{"issue":"1","key":"7686_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13550-021-00761-2","volume":"11","author":"P Windisch","year":"2021","unstructured":"Windisch P, et al. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review. EJNMMI Res. 2021;11(1):18.","journal-title":"EJNMMI Res"},{"issue":"5","key":"7686_CR19","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-020-05129-7","volume":"48","author":"Y Luo","year":"2021","unstructured":"Luo Y, et al. Active uptake of 68Ga-FAPI in Crohn\u2019s disease but not in ulcerative colitis. Eur J Nucl Med Mol Imaging. 2021;48(5):1682\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7686_CR20","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00259-023-06107-5","volume":"50","author":"L Chen","year":"2023","unstructured":"Chen L, et al. [68Ga]Ga-FAPI-04 PET\/CT on assessing Crohn\u2019s disease intestinal lesions. Eur J Nucl Med Mol Imaging. 2023;50(5):1360\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"26","key":"7686_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317(26):1625\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"7686_CR22","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324\u201338.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"7686_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2967\/jnumed.122.264361","volume":"64","author":"M Lang","year":"2023","unstructured":"Lang M, et al. Static and dynamic 68Ga-FAPI PET\/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas. J Nucl Med. 2023;64(2):244\u201351.","journal-title":"J Nucl Med"},{"issue":"6","key":"7686_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.123.267103","volume":"65","author":"M R\u00f6hrich","year":"2024","unstructured":"R\u00f6hrich M, et al. Diagnostic potential of supplemental static and dynamic 68Ga-FAPI-46 PET for primary 18F-FDG\u2013negative pulmonary lesions. J Nucl Med. 2024;65(6):872\u20139.","journal-title":"J Nucl Med"},{"issue":"12","key":"7686_CR25","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2967\/jnumed.122.264069","volume":"63","author":"FM Glatting","year":"2022","unstructured":"Glatting FM, et al. Repetitive early 68Ga-FAPI PET acquisition comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI74: methodologic and diagnostic implications for malignant, inflammatory\/reactive, and degenerative lesions. J Nucl Med. 2022;63(12):1844\u201351.","journal-title":"J Nucl Med"},{"issue":"11","key":"7686_CR26","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1136\/gutjnl-2023-329964","volume":"72","author":"MF Neurath","year":"2023","unstructured":"Neurath MF, Vieth M. Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing. Gut. 2023;72(11):2164\u201383.","journal-title":"Gut"},{"key":"7686_CR27","doi-asserted-by":"crossref","unstructured":"Annese, V. et al. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn\u2019s and Colitis. 2013;7(12):982\u2013 1018.35.","DOI":"10.1016\/j.crohns.2013.09.016"},{"issue":"3","key":"7686_CR28","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222389","volume":"307","author":"M Scharitzer","year":"2023","unstructured":"Scharitzer M, et al. Evaluation of intestinal fibrosis with 68Ga-FAPI PET\/MR enterography in Crohn disease. Radiology. 2023;307(3):e222389.","journal-title":"Radiology"},{"issue":"9","key":"7686_CR29","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1093\/rheumatology\/keae225","volume":"63","author":"M R\u00f6hrich","year":"2024","unstructured":"R\u00f6hrich M, et al. Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission. Rheumatology. 2024;63(9):2473\u201383.","journal-title":"Rheumatology"},{"issue":"11","key":"7686_CR30","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/annrheumdis-2020-217408","volume":"79","author":"C Schmidkonz","year":"2020","unstructured":"Schmidkonz C, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79(11):1485\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7686_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/ph17060716","volume":"17","author":"D Albano","year":"2024","unstructured":"Albano D, et al. The role of fibroblast activation protein inhibitor positron emission tomography in inflammatory and infectious diseases: an updated systematic review. Pharmaceuticals. 2024;17(6):716.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"7686_CR32","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s00259-023-06135-1","volume":"50","author":"P Lovinfosse","year":"2023","unstructured":"Lovinfosse P, et al. Commentary to \u201c[68 Ga]Ga-FAPI-04 PET\/CT on assessing Crohn\u2019s disease intestinal lesions\u201d by Chen and colleagues. Eur J Nucl Med Mol Imaging. 2023;50(5):1278\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07686-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07686-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07686-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:28Z","timestamp":1774401988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07686-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7686"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07686-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were approved by the local ethics committee and carried out in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study received approval from the Ethical Committee of the University hospital Heidelberg (Study number S-115\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for participation was obtained from all individual participants included in the study, and the investigation was conducted according to national regulatory laws.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}